Median Ki-97 proliferation index 5% (72% of cases were assessable)
Median of 3 tumor measurements prior to treatment
Median duration of repeat measurements was 21.7 months
Median Individual Radiological Growth Rate (IGR) 4.4 mm/year
Two Groups: 121 <8mm/year à low risk (LR) and 22 >8mm/year à high risk (HR)
No significant difference between the 2 groups regarding various demographics and treatment factors except that more biopsies done in LR group
Median clinical follow-up after radiologic diagnosis was 6.5 years
18.1% of LR patients died during this time versus 45.5% in HR group; median time to death was 6.7 years in LR group and 4.9 years in HR group
Median survival was 5.16 years in HR group versus 15 years in LR group
Univariate Analysis: inverse correlation between IGR and survival (p<0.001); histology, tumor volume, age, neurologic deficits, and Ki-67 proliferation score not significant predictors of survival
Multivariate Analysis: IGR (p<0.0001) and tumor volume (p=0.034) were independent prognostic factors for survival
IGR measurements prior to treatment in supratentorial grade II gliomas are predictive of prognosis
Previous studies have shown age >40, astrocytoma histology, tumor diameter >6 cm, neurologic defects, and lesions crossing midline have worse prognosis.
Lack of significance for several other prognostic factors may be due to small sample size.
Limitations of histologic diagnosis
Limited because it is "static"
Limited to part of the tumor, particularly in biopsies or partial resections
Conversely, tumor growth rate a macroscopic, dynamic parameter
In tumors growing >8 mm/year, worse prognosis despite absence of anaplastic transformation à seem to behave more like anaplastic gliomas with median survival of 5.16 years
Study may be limited as 2 MRIs may not accurately determine growth velocity
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.